BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 26, 2026
Home » Topics » Conferences

Conferences
Conferences RSS Feed RSS

Glowing neural network inside a transparent capsule surrounded by a large language model
Anglonordic Conference

Pharma industry faces long haul to get return on investment from AI

April 23, 2026
By Nuala Moran
No Comments
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on investment (ROI). “I would say a lot of companies sort of get this big excitement about AI, but then when you look at how much ROI they get, it’s actually very little. And that’s because the workflow and the process, end-to-end, isn’t mapped to really understand where AI can truly make an impact,” said Laura Matz, chief science and technology officer at Merck KGaA.
Read More
3d rendering of bispecific antibodies
Immuno-oncology

INCA-036873 appears to be potent in CD70-expressing cancer

April 23, 2026
No Comments
Incyte Corp. has developed and presented data for their CD70xCD3 bispecific antibody INCA-036873, which was designed to activate T cells and kill tumoral cells expressing CD70.
Read More
Silhouette of head and brainwith fractal art
Neurology/psychiatric

Synendos’ first-in-class SERI effective in models of anxiety

April 23, 2026
No Comments
At the recently concluded meeting of the American Academy of Neurology, Synendos Therapeutics AG reported preclinical data from the pharmacological characterization of SYT-510, which is the first selective endocannabinoid reuptake inhibitor (SERI) to enter the clinic for the potential treatment of disorders affecting the CNS, such as anxiety or movement disorders. A new class of endocannabinoid system (ECS) modulators, SERIs potently and selectively inhibit endocannabinoid reuptake to help the ECS restore normal brain function under disease conditions.
Read More
Illustration of human face that looks abstract and digital
Cancer

AACR 2026: The age of agentic AI in oncology

April 23, 2026
By Mar de Miguel
No Comments
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of experimental compounds fail in clinical trials, underscoring the need for strategies that better capture human biology. Many of these techniques were showcased at the 2026 American Association for Cancer Research (AACR) annual meeting.
Read More
Pancreas anatomy illustration
AACR 2026

Akeso sets durability bar as immuno-oncology 2.0 race heats up

April 22, 2026
By Tamra Sami
No Comments
Akeso Pharmaceuticals Inc. has raised the bar for next-generation immuno-oncology, reporting more than 23 months median overall survival in pancreatic cancer with its PD-1/CTLA-4 bispecific antibody cadonilimab, as emerging competitors begin to post earlier signals across solid tumors at the American Association for Cancer Research annual meeting in San Diego April 17 to 22.
Read More
Health care worker with IV drip
AACR 2026

Netrin-1 inhibitor blocks chemo resistance in pancreatic cancer

April 22, 2026
By Nuala Moran
No Comments
Netris Pharma SA has delivered positive phase Ib data showing its first-in-class netrin-1 inhibitor NP-137 alleviates resistance to chemotherapy in pancreatic cancer. This could represent an important advance in treating these tumors, which are notoriously resistant to chemotherapy.
Read More
Targeted cancer cell
AACR 2026

Revolution rocks on with first-line PDAC data at AACR

April 22, 2026
By Jennifer Boggs
No Comments
And the positive news continues to flow for Revolution Medicines Inc. On the heels of a successful phase III trial for RAS inhibitor daraxonrasib in previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC) – not to mention the firm pricing the largest follow-on offering in biopharma history – Revolution presented updated phase I/II data at the American Association for Cancer Research (AACR) meeting detailing impressive findings in first-line PDAC patients.
Read More
Woman stretching her arms and hands
AAN 2026

Walking the talk, Kyverna phase II stiffens miv-cel CAR T case

April 22, 2026
By Randy Osborne
No Comments
Optimism rose for what could be the first CAR T therapy in autoimmune disease as Kyverna Therapeutics Inc. made public a positive primary analysis from its registrational trial, KYSA-8, of mivocabtagene autoleucel (miv-cel, KYV-101) in stiff-person syndrome. Kyverna plans to submit a BLA to the U.S. FDA in the first half of this year.
Read More
Illustration of a cluster of ovarian cancer cells
Immuno-oncology

Cymirafen ADC exerts antitumor activity in ovarian cancer

April 22, 2026
No Comments
Cymirafen is a novel antibody-drug conjugate (ADC) from the University of California that targets leucine-rich repeat-containing G-protein coupled receptor 4 (LGR4)/LGR5/LGR6 and is composed of a potent cytotoxic payload, monomethyl auristatin E (MMAE), plus an Fc domain fused to the receptor binding domain of RSPO1.
Read More
Artistic rendering of the KRAS protein.
Cancer

Cogent Biosciences reports selective pan-KRAS inhibitor CGT-1263

April 22, 2026
No Comments
Researchers from Cogent Biosciences Inc. presented the preclinical profile of CGT-1263, a pan-KRAS-directed compound that binds both ON and OFF KRAS conformations without affecting HRAS or NRAS.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 12 … 3203 3204 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Brain and DNA

    Sangamo presents primate data for prion suppressor ST-506

    BioWorld Science
    Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
  • TREM2 agonists detailed in Pfizer patent

    BioWorld Science
    Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 26, 2026
  • Female uterus and ovaries on abstract scientific background

    Menstrual ‘footprints’ may act as broad personal health markers

    BioWorld
    WAVES, an algorithm designed to extract menstrual-cycle metrics from physiological signals such as basal body temperature, which oscillates with sex hormones,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing